Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin.
. The review is devoted to the most important aspects of primary mixed dyslipidemia treatment in patients at high risk with concomitant metabolic comorbidities. Evidences for novel modern approaches regarding primary prevention of cardiovascular events among dyslipidemic patients are considered. Th...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dnipro State Medical University
2015-06-01
|
| Series: | Medičnì Perspektivi |
| Subjects: | |
| Online Access: | http://journals.uran.ua/index.php/2307-0404/article/view/45652 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850283352283676672 |
|---|---|
| author | A. E. Berezin T. V. Sheychenko T. A. Berezina N. V. Vishnevaya N. V. Kovalenko Z. I. Kulik I. А. Мoiseenko |
| author_facet | A. E. Berezin T. V. Sheychenko T. A. Berezina N. V. Vishnevaya N. V. Kovalenko Z. I. Kulik I. А. Мoiseenko |
| author_sort | A. E. Berezin |
| collection | DOAJ |
| description | . The review is devoted to the most important aspects of primary mixed dyslipidemia treatment in patients at high risk with concomitant metabolic comorbidities. Evidences for novel modern approaches regarding primary prevention of cardiovascular events among dyslipidemic patients are considered. The potential role of lipid-lowering treatment with statins and their role in reducing the cardiovascular risk are discussed. Information about modern methods of minimization of residual cardiovascular risk using a combined lipid-lowering strategies and new representatives of the statins are provided.Ithasbeendiscussedvariousstrategiesofstatinadministeringtopatientswithdyslipidemiaof different agewith exiting comorbidities, such as diabetes mellitus, obesity, metabolic syndrome. Objective findingsand treatment approaches obtainedfromthe patientwithobesity, metabolic syndrome, and asymptomatic atherosclerosis are provided. The role of pitavastatin in primary prevention program of cardiovascular events is discussed. |
| format | Article |
| id | doaj-art-8b47a232fb3d4025826af843b1f015f4 |
| institution | OA Journals |
| issn | 2307-0404 |
| language | English |
| publishDate | 2015-06-01 |
| publisher | Dnipro State Medical University |
| record_format | Article |
| series | Medičnì Perspektivi |
| spelling | doaj-art-8b47a232fb3d4025826af843b1f015f42025-08-20T01:47:48ZengDnipro State Medical UniversityMedičnì Perspektivi2307-04042015-06-01202546210.26641/2307-0404.2015.2.4565245652Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin.A. E. BerezinT. V. SheychenkoT. A. BerezinaN. V. VishnevayaN. V. KovalenkoZ. I. KulikI. А. Мoiseenko. The review is devoted to the most important aspects of primary mixed dyslipidemia treatment in patients at high risk with concomitant metabolic comorbidities. Evidences for novel modern approaches regarding primary prevention of cardiovascular events among dyslipidemic patients are considered. The potential role of lipid-lowering treatment with statins and their role in reducing the cardiovascular risk are discussed. Information about modern methods of minimization of residual cardiovascular risk using a combined lipid-lowering strategies and new representatives of the statins are provided.Ithasbeendiscussedvariousstrategiesofstatinadministeringtopatientswithdyslipidemiaof different agewith exiting comorbidities, such as diabetes mellitus, obesity, metabolic syndrome. Objective findingsand treatment approaches obtainedfromthe patientwithobesity, metabolic syndrome, and asymptomatic atherosclerosis are provided. The role of pitavastatin in primary prevention program of cardiovascular events is discussed.http://journals.uran.ua/index.php/2307-0404/article/view/45652dyslipidemiacardiometabolic riskstatinspitavastatin |
| spellingShingle | A. E. Berezin T. V. Sheychenko T. A. Berezina N. V. Vishnevaya N. V. Kovalenko Z. I. Kulik I. А. Мoiseenko Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin. Medičnì Perspektivi dyslipidemia cardiometabolic risk statins pitavastatin |
| title | Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin. |
| title_full | Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin. |
| title_fullStr | Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin. |
| title_full_unstemmed | Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin. |
| title_short | Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin. |
| title_sort | primary dyslipidemia and cardiometabolic risk potential of pitavastatin |
| topic | dyslipidemia cardiometabolic risk statins pitavastatin |
| url | http://journals.uran.ua/index.php/2307-0404/article/view/45652 |
| work_keys_str_mv | AT aeberezin primarydyslipidemiaandcardiometabolicriskpotentialofpitavastatin AT tvsheychenko primarydyslipidemiaandcardiometabolicriskpotentialofpitavastatin AT taberezina primarydyslipidemiaandcardiometabolicriskpotentialofpitavastatin AT nvvishnevaya primarydyslipidemiaandcardiometabolicriskpotentialofpitavastatin AT nvkovalenko primarydyslipidemiaandcardiometabolicriskpotentialofpitavastatin AT zikulik primarydyslipidemiaandcardiometabolicriskpotentialofpitavastatin AT iamoiseenko primarydyslipidemiaandcardiometabolicriskpotentialofpitavastatin |